title: [In vitro oocyte maturation for safer treatment of infertility. The risk of ovarian overstimulation syndrome is minimized].
abstract: Ovarian hyperstimulation syndrome is a well known side effect of hormone stimulation in assisted reproduction. New treatments using minimal amounts of gonadotropins or no hormone supplementation may reduce this risk. In-vitro maturation (IVM) is a treatment where final oocyte maturation is achieved in the laboratory. Results have been acceptable and this method may provide a low-risk and cost-effective alternative to traditional IVF. IVM would thus avoid the high amounts of exogenous gonadotropins required for controlled ovarian hyperstimulation. Currently, only a few teams internationally are pursuing research in this field of human reproduction. IVM is a promising treatment alternative and can be recommended especially for patients at risk of developing ovarian hyperstimulation syndrome.
authors.affiliation: Enheten för obstetrik och gynekologi, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden. Julius.Hreinsson@kus.se
authors.forename: Julius
authors.initials: J
authors.lastname: Hreinsson
authors.forename: Margareta
authors.initials: M
authors.lastname: Fridström
mesh_terms: D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods* / Q000592:standards; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007247:Infertility, Female / Q000191:economics / Q000628:therapy; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development*; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D011247:Pregnancy; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D006063:Chorionic Gonadotropin; D005640:Follicle Stimulating Hormone